NCT05581160Completed
Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)
Source: ClinicalTrials.gov · Last updated 8 Oct 2024
Brief summary (registry, in English)
The main objective of the study will be to assess the performance of the Next-Generation-Sequencing (NGS) diagnostics of Chlamydia trachomatis and Neisseria gonorrhoeae compared to reference techniques.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 332 (actual)
- First submitted
- 12 Oct 2022
- Start date
- 11 Jul 2022
- Primary completion date
- 27 Sept 2024
- Lead sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
- Diseases
- HIV
- NCT number
- NCT05581160
What you commit to
- Study type: Interventional
- Participants enrolled: 332
- From 11 Jul 2022 to the primary completion date, 27 Sept 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Language barrier making questioning impossible.
Who the study is looking for
- Age ≥ 18 years old
- MSM
- PrEP users
- Acceptance of study constraints
- With or without Social Security scheme or State Medical Aid
- Signature of consent form to participate in the study
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Service des Maladies Infectieuses et Tropicales Hôpital Tenon Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| Service des Maladies Infectieuses et Tropicales Hôpital Saint-Antoine Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.